Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings

The Parkinson Associated Risk Syndrome Study identified a cohort of healthy adults with hyposmia and dopamine transporter binding reduction to characterize individuals at risk for Parkinson's disease (PD). We describe the cognitive profile of this cohort.

[1]  Roger L Albin,et al.  Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study , 2015, Neurology.

[2]  D. Aarsland,et al.  Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[3]  D. Berg,et al.  Prodromal features for Parkinson's disease – baseline data from the TREND study , 2014, European journal of neurology.

[4]  J. Molinuevo,et al.  Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients , 2014, PloS one.

[5]  A. Yang,et al.  Risk of Parkinson disease after depression , 2013, Neurology.

[6]  Bill Y. Lin,et al.  Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care , 2013, Neuroscience & Biobehavioral Reviews.

[7]  R. Strong,et al.  Cognitive Dysfunction Precedes the Onset of Motor Symptoms in the MitoPark Mouse Model of Parkinson’s Disease , 2013, PloS one.

[8]  Ralph H. B. Benedict,et al.  Hopkins Verbal Learning Test--Revised , 2013 .

[9]  N. Bohnen,et al.  In vivo neurochemical imaging of olfactory dysfunction in Parkinson’s disease , 2013, Journal of Neural Transmission.

[10]  C. Tanner,et al.  Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[11]  Danna Jennings,et al.  Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study , 2012, Movement disorders : official journal of the Movement Disorder Society.

[12]  K. Jellinger,et al.  Critical evaluation of the Braak staging scheme for Parkinson's disease , 2010, Annals of neurology.

[13]  R. Albin,et al.  Cholinergic denervation occurs early in Parkinson disease , 2009, Neurology.

[14]  H. Berendse,et al.  Hyposmia and executive dysfunction as predictors of future Parkinson's disease: A prospective study , 2009, Movement disorders : official journal of the Movement Disorder Society.

[15]  D. Aarsland,et al.  Cognitive impairment in incident, untreated Parkinson disease , 2009, Neurology.

[16]  A. Siderowf,et al.  Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment , 2008, Annals of neurology.

[17]  T. McGlashan,et al.  Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study , 2008, Schizophrenia Research.

[18]  M. Vendette,et al.  Executive dysfunction and memory impairment in idiopathic REM sleep behavior disorder , 2008, Neurology.

[19]  C. Brayne,et al.  A systematic review of depression and mental illness preceding Parkinson's disease , 2006, Acta neurologica Scandinavica.

[20]  L. Bäckman,et al.  The role of the striatal dopamine transporter in cognitive aging , 2005, Psychiatry Research: Neuroimaging.

[21]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[22]  C. Tanner,et al.  Frequency of bowel movements and the future risk of Parkinson’s disease , 2001, Neurology.

[23]  K. Marder,et al.  Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. , 2000, The American journal of psychiatry.

[24]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[25]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[26]  C. Clifford Attkisson,et al.  Screening for Depression in Primary Care Clinics: The CES-D and the BDI , 1990, International journal of psychiatry in medicine.

[27]  R. Doty,et al.  Development of the university of pennsylvania smell identification test: A standardized microencapsulated test of olfactory function , 1984, Physiology & Behavior.

[28]  G. Spears,et al.  Some norms and reliability data for the State--Trait Anxiety Inventory and the Zung Self-Rating Depression scale. , 1983, The British journal of clinical psychology.

[29]  Philip Schatz,et al.  Repeatable Battery for the Assessment of Neuropsychological Status , 2018 .

[30]  T. Foltynie,et al.  The ongoing pursuit of neuroprotective therapies in Parkinson disease , 2015, Nature Reviews Neurology.

[31]  C. Tanner,et al.  Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. , 2012, Parkinsonism & related disorders.

[32]  David Wechsler,et al.  Wechsler Memory scale. , 2005 .

[33]  J. Seibyl,et al.  Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[34]  J. Seibyl,et al.  Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  O. Spreen,et al.  A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary , 1991 .

[36]  C. Spielberger,et al.  Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire" , 1983 .